59
Days Left
Lead Plaintiff Deadline
Nov 16, 2026
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material facts concerning the true state of Ardelyx’s commercial performance and growth prospects for XPHOZAH and IBSRELA, and in particular the increasing payer-related access and reimbursement barriers affecting patient access, more stringent prior authorization requirements and step edit requirements that slowed new-patient starts and delayed prescription fulfillment. On August 6, 2026, Ardelyx issued a press release a reduction in its full-year 2026 IBSRELA revenue guidance and withdrawal of its long-term XPHOZAH revenue guidance. Management attributed the reduction on significantly increased payer utilization-management processes that restricted patient access to IBSRELA and slowed new-patient starts. Further, Defendants withdrew their long-term XPHOZAH revenue guidance due to “evolving market dynamics” and uncertainty regarding future growth projections. On this news, the price of Ardelyx’s common stock declined dramatically. From a closing market price of $4.87 per share on August 6, 2026, Ardelyx’s stock price fell to $4.00 per share on August 7, 2026, a decline of about 18% in the span of just a single day.
Investors who purchased or otherwise acquired Ardelyx, Inc. securities within the class period described above and suffered losses may be eligible.
If you suffered a loss in Ardelyx, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until November 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
● The Allegation: The complaint alleges that Ardelyx made materially false and misleading statements about its commercial performance and revenue outlook for its two core drugs, IBSRELA and XPHOZAH, while allegedly concealing increasingly restrictive payer requirements, more stringent prior authorization rules, and step edits that slowed new-patient starts and delayed prescription fulfillment.
● The Stock Drop: On August 7, 2026, ARDX fell $0.87 (about 18%) to $4.00 per share, down from a closing price of $4.87 per share on August 6, 2026, after the company cut its full-year 2026 IBSRELA revenue guidance and withdrew its long-term XPHOZAH revenue guidance.
● Class Period & Defendants: The class period runs from January 13, 2025 through August 6, 2026, inclusive. The named defendants are Ardelyx, Inc., Michael Raab (President, Chief Executive Officer, and Director), Justin Renz (Chief Financial Officer through November 4, 2025), Susan Hohenleitner (Chief Financial Officer from November 4, 2025), and Eric Foster (Chief Commercial Officer).
● Lead Plaintiff Deadline: November 16, 2026. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.
|
Ardelyx Class Action Summary |
|
|
Company |
Ardelyx, Inc. (NASDAQ: ARDX) |
|
Lead Plaintiff Deadline |
November 16, 2026 |
|
Class Period |
January 13, 2025 – August 6, 2026 |
|
Stock Drop |
August 7, 2026 – ARDX fell $0.87 (about 18%) to $4.00 |
A securities class action lawsuit has been filed against Ardelyx, Inc. (NASDAQ: ARDX). The case was brought by plaintiff Virgil Broadwater on behalf of investors who bought Ardelyx common stock. The class period runs from January 13, 2025 through August 6, 2026.
The complaint alleges that Ardelyx made materially false and misleading statements about its two core drugs, IBSRELA and XPHOZAH. The company touted its revenue guidance and long-term growth targets for both products. But the lawsuit claims Ardelyx hid growing payer and patient-access barriers. It says more stringent prior authorization rules and step edits were slowing new-patient starts and delaying prescription fulfillment.
According to the complaint, the alleged truth emerged after the market closed on August 6, 2026. Ardelyx cut its full-year 2026 IBSRELA guidance and pulled its long-term XPHOZAH target. The next day, ARDX stock fell about 18% to $4.00 per share. The complaint alleges that investors suffered losses following the disclosure.
Ardelyx, Inc. is a Delaware corporation headquartered in Waltham, Massachusetts, that develops and commercializes medicines. Its two core products are IBSRELA (tenapanor), for the treatment of irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), for reducing serum phosphorus in adults with chronic kidney disease on dialysis. The company's common stock trades on the NASDAQ Stock Market under the ticker symbol ARDX.
January 13, 2025 – August 6, 2026
Investors who purchased or otherwise acquired Ardelyx, Inc. (ARDX) common stock during the Class Period may be eligible to seek recovery under the federal securities laws.
The complaint centers on Ardelyx's two commercial drugs, IBSRELA and XPHOZAH, and the revenue projections defendants provided to investors throughout the class period. According to the complaint, defendants repeatedly expressed confidence in the company's continued commercial growth, its ability to execute its commercial strategy to overcome payer and patient-access barriers, and its ability to achieve projected revenue guidance and long-term growth targets. The named defendants include Chief Executive Officer Michael Raab, former Chief Financial Officer Justin Renz, current Chief Financial Officer Susan Hohenleitner, and Chief Commercial Officer Eric Foster.
Beginning with a January 13, 2025 press release, the complaint alleges defendants announced approximately $319 million in 2024 U.S. net product sales and reaffirmed peak annual sales expectations of $750 million for XPHOZAH and more than $1 billion for IBSRELA. At the J.P. Morgan Healthcare Conference on January 15, 2025 and on subsequent earnings and investor conference calls, defendants highlighted investments in patient-services infrastructure, including the ArdelyxAssist program, field reimbursement managers, and sales-force expansion, which they said were driving prescription pull-through and patient access. The lawsuit points to statements on February 20, 2025, May 1, 2025, August 4, 2025, October 30, 2025, February 19, 2026, and April 30, 2026 earnings calls, along with several investor conferences, in which management reaffirmed and at times raised guidance.
The complaint alleges these statements were materially false and misleading because defendants concealed the true state of the company's commercial performance and growth prospects. In particular, the lawsuit claims defendants failed to disclose increasing payer-related access and reimbursement barriers, more stringent prior authorization requirements, and step edit requirements that slowed new-patient starts and delayed prescription fulfillment for IBSRELA while undermining XPHOZAH's long-term growth prospects.
The complaint further alleges that defendants knew or recklessly disregarded that these adverse facts had not been disclosed to the public. It notes that defendants reaffirmed both IBSRELA and XPHOZAH full-year 2026 revenue guidance on April 30, 2026, just three months before the August guidance cut, while continuing to report improving prescription pull-through.
The truth emerged after the market closed on August 6, 2026, when Ardelyx issued a press release announcing its second quarter 2026 financial results. According to the complaint, the release revealed that IBSRELA revenue was below expectations due to significantly increased utilization-management processes from payers. Defendants cut full-year 2026 IBSRELA guidance from a range of $410 million to $430 million down to $350 million to $370 million and withdrew their long-term XPHOZAH revenue guidance, citing evolving market dynamics and uncertainty regarding future growth projections.
On the accompanying earnings call, the complaint alleges, Chief Commercial Officer Eric Foster acknowledged significant payer hurdles affecting IBSRELA patient access and slowing new-patient starts. The lawsuit states that management admitted it was seeing more step edits and more stringent prior authorizations, which slowed new-patient conversion rather than permanently blocking access. These disclosures, according to the complaint, directly contradicted defendants' prior statements throughout the class period touting commercial growth, sustained product demand, and the effectiveness of the company's patient-access initiatives.
The complaint notes that several analysts lowered their price targets in response. Wedbush cut its price target by 53%, Citigroup dropped its target 21% to $11, and Leerink Partners lowered its target 19%, with analysts attributing the shortfall to a rapid increase in payer restrictions, including more stringent prior authorizations and expanded step-edit requirements that slowed new patient starts and delayed prescription fulfillment.
Investors and analysts reacted immediately to the disclosure. According to the complaint, Ardelyx common stock fell from a closing price of $4.87 per share on August 6, 2026 to $4.00 per share on August 7, 2026, a decline of about 18% in the span of a single trading day. The lawsuit alleges this decline reflected the removal of prior artificial inflation from the stock price after defendants disclosed the increasing payer and market-access challenges, the downward revision to previously reiterated full-year 2026 revenue guidance, and the withdrawal of the company's long-term XPHOZAH target.
● Lead Plaintiff Deadline: November 16, 2026
● After the lead plaintiff deadline, the Court will consider any lead plaintiff motions.
● Defendants may file a motion to dismiss.
● If the case proceeds, the Court may later consider class certification.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.
The Ardelyx securities class action lawsuit concerns allegations that the company and certain officers made materially false and misleading statements about the commercial performance and growth prospects of its two core drugs, IBSRELA and XPHOZAH. According to the complaint, defendants touted revenue guidance and long-term targets while concealing increasingly restrictive payer requirements, more stringent prior authorization rules, and step edits that slowed new-patient starts and delayed prescription fulfillment. The complaint alleges these facts emerged on August 6, 2026, when Ardelyx cut its 2026 IBSRELA guidance and withdrew its long-term XPHOZAH target.
The lawsuit is brought on behalf of investors who purchased or otherwise acquired Ardelyx common stock during the class period, which runs from January 13, 2025 through August 6, 2026, inclusive. According to the complaint, these investors purchased ARDX shares at prices that were allegedly artificially inflated by the defendants' statements. Investors who purchased or otherwise acquired Ardelyx common stock during this period and suffered financial losses may be eligible to seek recovery under the federal securities laws.
According to the complaint, Ardelyx allegedly concealed that it was experiencing increasing payer-related access and reimbursement barriers affecting patient access to its drugs. The lawsuit claims that more stringent prior authorization requirements and step edit requirements were slowing new-patient starts for IBSRELA and delaying prescription fulfillment, while undermining XPHOZAH's long-term growth prospects. The complaint alleges defendants continued to express confidence in achieving revenue guidance and long-term targets while these headwinds were developing, including reaffirming 2026 guidance on April 30, 2026, just months before the August guidance cut.
The complaint alleges that after Ardelyx disclosed its second quarter 2026 results and revised guidance after the market closed on August 6, 2026, the stock declined dramatically. ARDX fell from a closing price of $4.87 per share on August 6, 2026 to $4.00 per share on August 7, 2026, a decline of about 18% in a single trading day. According to the complaint, several analysts also lowered their price targets in response, with Wedbush cutting its target by 53%, Citigroup by 21%, and Leerink Partners by 19%.
The defendants named in the complaint are Ardelyx, Inc. and four individual officers. They are Michael Raab, President, Chief Executive Officer, and Director; Justin Renz, who served as Chief Financial Officer until November 4, 2025; Susan Hohenleitner, who was appointed Chief Financial Officer effective November 4, 2025 and continues to serve in that role; and Eric Foster, Chief Commercial Officer. The complaint alleges that because of their positions, these individuals possessed the power and authority to control the contents of Ardelyx's reports to the SEC, press releases, and presentations to securities analysts and investors.
The lead plaintiff deadline is November 16, 2026.
A lead plaintiff is an investor selected by the court to represent the interests of the entire class in a securities class action. Under the federal securities laws, the court typically appoints the investor with the largest financial interest in the case who otherwise meets the applicable requirements. The lead plaintiff helps direct the litigation on behalf of all class members. Investors are not required to serve as lead plaintiff to participate in any potential recovery, but those who wish to seek appointment must apply by the applicable deadline.
The Ardelyx securities class action alleges the company made materially false and misleading statements about the growth prospects of its IBSRELA and XPHOZAH drugs, allegedly concealing payer restrictions and prior authorization hurdles that slowed new-patient starts and delayed prescription fulfillment.
Investors who purchased or acquired Ardelyx (ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive, may be eligible to seek recovery under the federal securities laws.
According to the complaint, ARDX fell from $4.87 per share on August 6, 2026 to $4.00 per share on August 7, 2026, a decline of about 18% in a single trading day after the company cut guidance.
The lead plaintiff deadline is November 16, 2026.
Deadline
Nov 16, 2026